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Abstract
Background: Epidemiological, preclinical, and non-interventional studies link vitamin D (VD) serum
levels and disease activity in multiple sclerosis (MS). It is unclear whether high-dose VD supplemen-
tation can be used as an intervention to reduce disease activity.
Objectives: The study aimed to compare the effects of every other day high- (20,400 IU) versus low-
dose (400 IU) cholecalciferol supplementation on clinical and imaging markers of disease activity in
patients with relapsing–remitting MS or clinically isolated syndrome.
Methods: The EVIDIMS (efficacy of vitamin D supplementation in multiple sclerosis) trial was a
multicentre randomized/stratified actively controlled explorative phase 2a pilot trial with a double-
blind intervention period of 18 months, add on to interferon-b1b.
Results: Fifty-three patients were randomized, and 41 patients completed the study. Cholecalciferol
supplementation was well tolerated and safe in both arms. After 18 months, clinical (relapse rates,
disability progression) and radiographical (T2-weighted lesion development, contrast-enhancing lesion
development, brain atrophy) did not differ between both treatment arms. Post-study power calculations
suggested that the sample size was too low to prove the hypothesis.
Conclusions: The results neither support nor disprove a therapeutic benefit of high-dose VD supple-
mentation but provide a basis for sound sample size estimations in future confirmatory studies. www.
clinicaltrials.gov/NCT01440062
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Introduction
Preclinical and epidemiological studies link
25-hydroxy (OH) vitamin D, hereafter referred to
as vitamin D, serum levels to disease activity of
multiple sclerosis (MS). In particular, associations
of higher vitamin D levels in patients with MS
with favourable clinical and magnetic resonance
imaging (MRI) parameters of disease activity
have been reported.1–3 Based on these data, MS
clinicians commonly boost vitamin D levels
in patients by oral cholecalciferol or ergocalciferol
supplementation.
While safety data are rather unequivocal and suggest
that vitamin D supplementation up to 280,000 IU/
week is fairly safe,4 prospective data from interven-
tional treatment trials of vitamin D supplementation
on clinical efficacy, doses needed, and optimal
serum levels in MS are sparse, inconsistent, and in
part conflicting.5,6 A phase I/II randomized con-
trolled open-label study comparing continuous
intake of up to 40,000 IU/day or 4000 IU/day
for 52 weeks in 49 patients with MS showed a sig-
nificant reduction of annualized relapse rate in the
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high-dose arm.7 In contrast, two randomized,
placebo-controlled and double-blind phase II trials
from Finland and Norway, applying 20,000 IU/week
cholecalciferol for 48 or 96 weeks, demonstrated no
effect of vitamin D on relapse rates.8,9 In the Finish
study, however, patients in the treatment group had
significantly fewer gadolinium enhancing (gdþ)
lesions and a tendency to reduced disability accumu-
lation.8 The placebo-controlled SOLAR study10
showed no effect of 14,000 IU cholecalciferol per
day on the primary endpoint ‘no evidence of disease
activity’ but a significant beneficial effect on the
development of new lesions on cranial MRI and a
trend towards a reduction of relapse rate.
The ‘efficacy of vitamin D supplementation in mul-
tiple sclerosis’ (EVIDIMS) clinical trial was an
investigator-sponsored randomized actively con-
trolled double-blind phase II trial of vitamin D sup-
plementation in patients with MS. The detailed
protocol has been published previously.11 Here, we
report the major clinical and MRI results.
Patients and methods
Study design and ethics statement
The EVIDIMS clinical trial was a multicentre, ran-
domized and stratified, active controlled, double-
blind, explorative phase II trial. Two doses of vita-
min D3 (cholecalciferol) were compared: in the
high-dose arm participants received 20,400 IU
(1ml cholecalciferol oil (20,000 IU)þ 1 tablet
(400 IU)) every other day for 18 months, while in
the low-dose arm 400 IU (1 ml placebo oil (0 IU)þ
1 tablet (400 IU)) were given every other day. To
rule out confounding effects of variable disease-
modifying treatments, all participants were required
to be on stable treatment with interferon-beta-1b,
started at least 3 months prior to inclusion.
Interferon-beta treatment was continued throughout
the study.
Patients with relapsing–remitting (RR)MS or clini-
cally isolated syndrome (CIS) were recruited at
seven German study centres (Berlin (four centres),
Potsdam, Halle, Teupitz; for details see supplemen-
tary information). After a short screening period eli-
gible patients were stratified according to gender and
vitamin D level (< or 20 ng/ml (50 nmol/l)) and
then randomized 1:1 to either high-dose or low-
dose treatment as an add-on to continuous treatment
with IFN b-1b. Clinical evaluations including
Expanded Disability Status Scale (EDSS)12 and MS
Functional Composite (MSFC)13 were performed at
screening and then every 6 months. Standardized
MRI was performed at screening and after 12 and 18
months using identical hardware for all patients (at the
Charite study centre, Berlin). Pharmacovigilance lab-
oratory testing was done after 4 weeks and thereafter
every 3 months.
The primary endpoint was the number of new
T2-weighted (T2w) hyperintense lesions on brain
MRI at month 18 compared with baseline. Major
secondary endpoints were relapse rate and disability
progression on the clinical side, T2w lesion volume,
number of gdþ lesions, and brain atrophy on
the MRI side, and number of adverse events on the
safety side. More detailed information on the design
and conduct of the EVIDIMS trial has been pub-
lished previously,11 and additional information is
provided as supplementary information. The study
protocol (in German) is available from the corre-
sponding author upon qualified request.
The study was approved by the German Federal
Institute for Drugs and Medical Devices (BfArM,
4037578), as well as by the local ethics committees
(11/0386-ZS EK 13) and is registered at European
Clinical Trials Database (EudraCT 2011-002785-20)
and ClinicalTrials.gov (NCT01440062). It was con-
ducted strictly adhering to the study protocol and
to applicable national laws (Arzneimittelgesetz, 14.
Novelle, 2005), the Harmonized Tripartite Guideline
for Good Clinical Practice (ICH GCP), and the prin-
ciples of the Declaration of Helsinki in its applicable
version. All participants gave written informed con-
sent at screening prior to any study-related procedures.
Study population
The main inclusion criteria were: male and female
patients with either CIS or a definite diagnosis of
MS according to the 2005 revised McDonald crite-
ria14 and a relapsing–remitting disease course; age at
randomization 18–65 years; EDSS score 0–6; con-
tinuous treatment with IFN b1b for at least
3 months; and no relapse within 30 days prior to
randomization. Important exclusion criteria were:
relevant hepatopathy or renal dysfunction; history
of sarcoidosis, nephrolithiasis, pseudo hypoparathy-
roidism; vitamin D supplementation >500 IU/day
within 6 months prior to randomization; pregnancy;
hypercalcaemia or urine calcium/creatinine ratio >1;
concomitant medication with hydrochlorothiazide,
digitoxin, digoxin, phenytoin, barbiturates; inability
to provide informed consent; incompatibility with
MRI procedures. A comprehensive listing of inclusion
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and exclusion criteria is provided in the supplementary
information.
Outcome measures
Clinical evaluations and safety laboratory tests.
All clinical evaluations and scorings were performed
by trained study personnel blinded to the patients’
treatment allocations according to standardized
operating procedures. MS relapses were defined as:
(re)occurrence of new or previous central nervous
system dysfunction in the absence of infections or
hyperthermia, duration 24 h, time-lag from the
onset of previous relapse 30 days. Disability was
assessed by EDSS and MSFC.12,13 EDSS rating was
performed by trained (Neurostatus) and board-certified
physicians otherwise not involved in the management
of study participants. MSFC scoring was done by
trained study personnel. All study-related safety labo-
ratory tests were done by Bioscientia laboratories
(Bioscientia Institut fu¨r Medizinische Diagnostik
GmbH, Ingelheim, Germany).
MRI. Standardized MRI was performed in all par-
ticipants in one study centre at Charite -
Universit€atsmedizin Berlin, using a Magnetom
TIM TRIO 3 Tesla MRI (Siemens Healthineers,
Erlangen, Germany). A sagittal 3D SPACE T2w
sequence (TR 5,000ms, TE 502ms, TI 900ms,
flip angle 9 degree, isotropic resolution 1mm3,
GRAPPA 2) was used to obtain T2w images.
In addition, we applied a 3D fluid-attenuated inver-
sion recovery sequence (SPACE-FLAIR, TR
6,000ms, TE 388ms, TI 2,100) with identical spatial
parameters, and a high-resolution 3-dimensional
T1w sequence (MPRAGE, TR 1,900ms, TE
3.03ms, TI 900ms, flip angle 9 degree, isotropic
resolution 1 mm3 GRAPPA 2) with identical spatial
parameters. A 3D T1w sequence (VIBE, TR 4.8ms,
TE 2.2ms, flip angle 9 degree, isotropic resolution
1mm3 GRAPPA 2) with identical spatial parameters
was applied 5 min after injection of 0.1mmol/kg gd-
DTPA (Gadovist, Bayer, Berlin, Germany). Raw
data were transferred to a Linux workstation and
processed following a semi-automated procedure,
including an image coregistration (FMRIB’s Linear
Image Registration Tool, FMRIB Analysis Group,
University of Oxford, Oxford, UK) and inhomoge-
neity correction routine embedded into the MedX
v.3.4.3 software package (Sensor Systems Inc.,
Sterling, VA, USA). T2w white matter lesion load,
as well as number and volume of contrast-enhancing
and hypointense lesions on T1w scans were routine-
ly measured using the MedX v.3.4.3 software
package. Brain atrophy (percentage brain volume
change (PBVC) and normalized brain volume
(NBV)) was estimated with SIENA,15 part of
FSL.16 Thalamic volumetry was performed using
FIRST (FMRIB Analysis Group, University of
Oxford, Oxford, UK).
Statistical analyses. Due to lack of data on the effect
of vitamin D on T2w lesions, no statistical sample
size calculation was performed in advance using a
given error of the 1st kind and stipulated power.
A sample size of 80 patients (40 in each arm) was
planned, based mainly on feasibility.
Due to the explorative character of the study, statis-
tical testing has to be understood as explorative, and
data analyses were mainly descriptive for all end-
points. For univariate independent group compari-
sons exact Mann–Whitney U tests and exact
Chi-Square tests were used. Survival data such as
MS relapses were analysed by Kaplan–Meier
curves with appropriate log-rank tests and multiple
Cox-regressions. For time series data, a nonparamet-
ric multivariate analysis of longitudinal data
(MANOVA) in a two-factorial design was applied
(1st factor (independent): treatment groups, 2nd
factor (dependent): study visits). When appropriate,
multivariate nonparametric analysis of covariance
(MANCOVA) using baseline values and additional
parameters including age, gender, and disease dura-
tion as covariates was complemented. The PBVC
was adjusted using baseline NBV. Missing values
were replaced by multiple imputations. Statistical
significance was assumed at the p¼ 0.05 level.
Because of the explorative nature of analyses, no
adjustments for multiple comparisons were per-
formed. Both intent-to-treat (ITT) and per-protocol
(PP) analyses were carried out. The ITT group com-
prised 53 patients. The PP definition was regular
study termination and protocol-conform study
drug intake. The PP group comprised 38 patients.
All calculations were performed using SAS
Version 9.4 [TS1M3] Copyright 2002–2012 by
SAS Institute Inc., Cary, NC, USA, IBM SPSS
Statistics, Version 25, Copyright 1989, 2010 SPSS
Inc., an IBM Company, Chicago, IL, USA and The
R Project for Statistical Computing, Version 3.0.2
(2017-04-21).
Results
Study population
After starting recruitment, the study was terminated
early. Fifty-three patients were randomized and
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included in the ITT analyses, 28 in the high-dose and
25 in the low-dose arm. Demographic baseline char-
acteristics (ITT population) are shown in Table 1.
T2w lesion volume was higher in the low-dose
arm (p¼ 0.01), and thalamic volume was higher in
the high-dose arm (p¼ 0.048). As shown in Figure 1,
41 participants completed the study. The number of
dropouts did not differ between both arms. The rea-
sons for dropping out are provided in the CONSORT
flow chart (Figure 1). Two patients in the high-dose
arm were excluded from analyses because of major
protocol violations, which resulted in an insufficient
increase of the serum vitamin D levels. In the low-
dose arm, one patient was excluded because of miss-
ing MRI data at baseline and final visit (Figure 1).
Thus, 38 patients were included in the PP analyses.
Vitamin D levels, MRI and clinical endpoints
Important explorative clinical and paraclinical out-
come parameters (univariate, ITT population) are
presented in Table 2. While on study medication,
25(OH)vitamin D levels increased from 19 (7–53)
ng/ml at baseline to 62 (52–80) ng/ml at month 18 in
the high-dose group and from 17 (4–35) to 23 (18–
27) ng/ml in the low-dose group (p< 0.001).
The primary endpoint, number of new T2w hyper-
intense lesions on brain MRI at month 18 compared
with baseline, was not different between arms, as
were T2w lesion counts (p¼ 0.15) when including
baseline, age, gender, and disease duration as cova-
riates in a MANCOVA for longitudinal data.
Similarly, T2 lesion volume at month 18 compared
with baseline was not different between arms
(p¼ 0.98). A numerical but not significant
(p¼ 0.09) higher number of cumulative new gdþ
lesions in the low-dose arm was driven by only
four patients. MANCOVA with baseline as covariate
showed no differences in the thalamic volume
(p¼ 0.95), PBVC (p¼ 0.84), and the brain paren-
chymal fraction (p¼ 0.43) (Table 2). Disease pro-
gression measured by median EDSS (p¼ 0.64) and
mean MSFC z-score (p¼ 0.31) in a MANCOVA
with baseline as covariate was not different in both
arms (Table 2).
Safety endpoints
The numbers and severity of adverse events did not
differ between groups (p¼ 0.5, exact Chi-Square
test). In total, 41 adverse events were recorded; of
these 23 were in the high-dose and 18 in the low-
dose arm. The most often recorded adverse events
were respiratory infections (n¼ 25) and musculo-
skeletal complaints (n¼ 15), but without differences
between study arms. The majority of adverse events
were mild or moderate and not considered related to
the study medication. No serious adverse events and
no vitamin D-related toxicity or safety issues were
recorded.
Table 1. Baseline characteristics of patients (ITT).
High dose Low dose p-value
Total (n) [within group (%)] 28 [53] 25 [47] >0.99a
Disease course (n)
RRMS 26 25 0.49a
CIS 2 0
Female [within group (%)] 20 [71] 17 [68] >0.99a
Mean age at screening (years) [SE] 41 [2.1] 45 [1.8] 0.26b
Mean disease duration onset to screening (months) [SE] 97 [14.4] 125 [16.8] 0.24b
Mean BMI at screening [SE] 27.2 [1.3] 25.5 [0.9] 0.61b
Median EDSS [range] 2.0 [5.0] 2.5 [6.0] 0.18b
Mean 25OH vitamin D serum level (ng/ml) [SE] 18.8 [1.9] 17.8 [1.7] 0.9b
Mean T2w lesion count (n) [SE] 52.6 [6.7] 76.1 [10.7] 0.08b
Mean T2w lesion volume (ml) [SE] 4.6 [0.9] 10.4 [1.9] 0.01b
Mean brain parenchymal fraction (ml) [SE] 1163.1 [25.8] 1121.3 [18.1] 0.4b
Mean thalamus volume (ml) [SE] 15.5 [0.4] 14.4 [0.4] 0.05b
Total gdþ lesions (n) 4 2 >0.99b
BMI: body mass index; CIS: clinically isolated syndrome; EDSS: Expanded Disability Status Scale; gdþ: gadolinium
enhancing lesions; ITT: intention to treat; MSFC: Multiple Sclerosis Functional Composite; n: number; RRMS:
relapsing remitting MS; SE: standard error.
aexact Chi-Square tests; bexact Mann–Whitney U test
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Figure 1. The CONSORT flow diagram.
Figure 1 shows the numbers of screened, randomized, and analysed patients in both treatment arms. The reasons for exclusion from randomization,
drop out or exclusion from analysis are displayed.
ITT: intention to treat; PP: per protocol; n: number.
Table 2. Main clinical and MRI outcome parameters after 18 months and the changes from baseline (ITT).
High dose Low dose p-value
Change from baseline
p-valueHigh dose Low dose
Mean 25OH vitamin D serum
level (ng/ml) [SE]
65.0 [5.5] 22.3 [1.4] <0.001c 45.9 [5.4] 5.9 [2.3] <0.001c
Cumulative number of relapses (n) 5 7 0.6b
Median EDSS [range] 2.0 [3.5] 2.0 [5.5] 0.26a 0 [4] 0 [2.5] 0.64c
Mean MSFC z-score change [SE] –0.24 [0.14] –0.44 [0.28] 0.13a 0.12 [0.07] –0.09 [0.16] 0.31c
Mean T2w lesion count (n) [SE] 53.4 [7.3] 84.1 [13.5] 0.05a 1.3 [0.1] 2.1 [1.4] 0.15c
Mean T2w lesion volume (ml) [SE] 3.6 [0.5] 11.9 [2.2] <0.001a 0.1 [0.1] 0.2 [0.3] 0.98c
Mean brain parenchymal fraction (ml) [SE] 1167.7 [25.9] 1126.6 [20.7] 0.97a –9.3 [3.7] –7.3 [2.6] 0.43c
Mean brain volume changes (%) [SE] 0.61 [0.12] 0.52 [0.10] 0.98a na na 0.84c
Mean thalamus volume (ml) [SE] 15.7 [0.3] 14.4 [0.5] 0.048a 0.41 [0.6] –0.12 [0.1] 0.95c
cumulative number of new
gdþ lesions (V0–V6) (–)
2 14 0.09a na na na
EDSS: Expanded Disability Status Scale; gdþ: gadolinium enhancing lesions; ITT: intention to treat; MSFC: Multiple Sclerosis Functional
Composite; n: number; SE: standard error; na: not applicable.
aexact Mann–Whitney U tests; bKaplan–Meier analysis, log-rank tests and multiple Cox regression; cmultivariate analysis of covariance
(MANCOVA) when including baseline values, age, gender and disease duration as covariates in a longitudinal analysis.
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Discussion
Upon 18 months of continuous vitamin D intake we
did not detect a different effect of high-dose versus
low-dose supplementation of MS patients on impor-
tant clinical and MRI parameters. We also did not
record any relevant vitamin D-related adverse
events. The study was carefully planned to account
for heterogeneity of patients and variability of data
(i.e. stratification, monocentric standardized MRI for
all patients, standardization of evaluation, separation
of treating and evaluating personnel). We chose an
actively controlled paradigm because we expected a
high incidence of vitamin D deficiency, and it was
considered ethically not justifiable to deprive partic-
ipants of any vitamin D supplementation. In fact, at
baseline, the mean serum vitamin D levels
were< 20 ng/ml in both arms (Table 1). The higher
dose (corresponding to 10,200 IU per day) was
chosen empirically under consideration of safety
aspects and was higher than the doses given in the
majority of previous trials,8,9 but was lower than the
treatment arm dose (14,007 IU) in the SOLAR
trial.10 The lower dose was derived from recommen-
dations of the German Nutrition Society at the time
when the study was designed, which were 200 IU
per day. One might speculate that the difference
between both doses was too low, or that already
the low dose was immunologically active. But the
observation of a rather small increase of the mean
vitamin D serum level in the low-dose arm (from 18
to 22 ng/ml) in contrast to the pronounced rise in the
high-dose arm argues against an insufficient differ-
ence between both doses. The rather mild disease
activity in the entire cohort, which might be
explained by the disease-modifying pretreatment
with IFN b and the add-on treatment paradigm to
an approved disease-modifying drug, may also
have contributed to the negative results. But from
an ethical point of view it was considered unaccept-
able to ‘treat’ MS patients with active disease
solely by vitamin D and to withhold an approved
treatment.
Finally, the rather small sample size may well
account for the lack of differences in both study
arms during therapy with a drug that significantly
reduces relapses and MRI activity. The targeted
sample size of 80 participants was mainly based on
feasibility and did not result from a statistically
supported sample size calculation. Nevertheless,
unforeseen recruitment difficulties such as the con-
temporaneous approval of oral MS drugs and a
highly comparative environment with a large
number of recruiting clinical trials may explain
why, despite a fairly long recruitment period of
45 months, only 53 patients were randomized.
A substantial dropout rate further reduced the
power to detect primary endpoint changes with
a¼ 0.05 (two-sided) to 11% (PP population) and
4% (ITT population), respectively. However, these
figures provide important information for future
trials on vitamin D supplementation in MS. To
detect a difference in the T2w lesion count with a
power of 80% and a type 1 error (a) of 0.05 (two-
sided) 252 participants (PP population) or 613 (ITT
population) per arm would be necessary. The corre-
sponding numbers for the hypothetical endpoint T2w
lesion volume would be 3147 or 33,202 participants
per arm. These power considerations suggest the in
principle feasibility to demonstrate (or disprove) a
disease-modifying effect of vitamin D supplementa-
tion in MS patients, at least for the endpoint T2w
lesion count.
Tolerability and safety even of the high-dose were
excellent in this study. The number of adverse events
was similar in both arms, and adverse events
recorded were not considered related to vitamin D
intake. Most importantly, we did not observe hyper-
calcaemia. Thus, the EVIDIMS trial suggests that a
mean daily intake of about 10,000 IU cholecalciferol
is safe, at least under the premises of the cohort
studied, i.e. in patients aged 25 to 62 without any
relevant kidney dysfunction and exclusion of certain
co-medications.
In conclusion, the results of the EVIDIMS study nei-
ther support nor disprove a beneficial effect of vita-
min D supplementation in MS. However, the
explorative trial results provide valuable information
for sample size calculation and feasibility of future
confirmatory trials on this topic. The data further sup-
port the safety and tolerability of a mean daily dose of
10,200 IU cholecalciferol in patients with MS.
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